Navigation Links
Rare genetic disease successfully reversed using stem cell transplantation
Date:9/17/2009

LA JOLLA, CA September 17, 2009 A recent study by Scripps Research Institute scientists offers good news for families of children afflicted with the rare genetic disorder, cystinosis. In research that holds out hope for one day developing a potential therapy to treat the fatal disorder, the study shows that the genetic defect in mice can be corrected with stem cell transplantation.

"After meeting the children who suffer from this disease, like an 18-year-old who has already had three kidney transplants, and the families who are desperately searching for help, our team is committed to moving toward a cure for cystinosis, a lysosomal storage disorder," says principal investigator Stephanie Cherqui, assistant professor in the Department of Molecular and Experimental Medicine. "This study is an important step toward that goal."

In the study, which is published in the September 17, 2009 print edition of the journal Blood, the Scripps Research team used bone marrow stem cell transplantation to address symptoms of cystinosis in a mouse model. The procedure virtually halted the cystine accumulation responsible for the disease and the cascade of cell death that follows.

Cystine is a byproduct of the break down of cellular components the body no longer needs in the cell's "housekeeping" organelles, called lysosomes. Normally, cystine is shunted out of cells, but in cystinosis a gene defect of the lysosomal cystine transporter causes it to build up, forming crystals that are especially damaging to the kidneys and eyes.

A Rare But Devastating Disease

While cystinosis is rareaffecting an estimated 500 people in the United States and 2,000 worldwideit is devastating. Three types of cystinosis have been described based on the age at diagnosis and the amount of cystine in cells: infantile onset, adolescent onset, and adult onset. Children as young as six months can begin to suffer renal dysfunction, which grows progres
'/>"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Does the desire to consume alcohol and tobacco come from our genetic makeup?
2. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
3. Many parents at-risk for cancer disclose genetic test results to children
4. Genetics determine optimal drug dose of common anticoagulant
5. Claims of sex-related differences in genetic association studies often not properly validated
6. American College of Medical Genetics responds to new FDA labeling decision for warfarin
7. UNC study questions FDA genetic-screening guidelines for cancer drug
8. Genome study shines light on genetic link to height
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
11. Rutgers Genetics receives $7.8 million for autism research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... in Antarctica, funded by the National Science Foundation (NSF), have ... and greenhouse gases in the atmosphere that extends back 68,000 ... the ice containing the record is known as the WAIS ... the core contain uniquely detailed information on past environmental conditions ...
... molds and fungi, bacteria and viruses. To kill them off ... are, as a rule, treated chemically. However, recently this method ... have been withdrawn, but the granting of new permits has ... E. coli infection which was caused by beansprout ...
... ARBORMany medically minded researchers are in hot pursuit of ... and the interiors of cells, but University of Michigan ... to overcome: escaping the bloodstream. Drug delivery ... medicines could be more effective at lower doses and ...
Cached Biology News:Antarctic ice core contains unrivaled detail of past climate 2Antarctic ice core contains unrivaled detail of past climate 3Healthy seeds -- treated environmentally friendly 2Healthy seeds -- treated environmentally friendly 3Achilles heel: Popular drug-carrying nanoparticles get trapped in bloodstream 2Achilles heel: Popular drug-carrying nanoparticles get trapped in bloodstream 3
(Date:12/13/2014)... 2014 The “Global Synthetic Biology ... drivers, threats, opportunities, and challenges. , The global ... players, namely, Thermo Fisher Scientific, Inc. (U.S.), DuPont ... jointly accounted for approximately ~65% of the total ... Copy for This Report @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html ...
(Date:12/13/2014)... York (PRWEB) December 13, 2014 QuickSTAT ... global network and Cold Chain capabilities, and is delighted ... in Paris, France, to serve Life Science clients in ... equipped with a controlled-ambient warehouse, will provide 24/7 transportation ... vaccines and investigational drugs, patient-clinical specimens, API, following IATA ...
(Date:12/13/2014)... 11, 2014 Research and Markets ... the "Glucose Sensors: the Next Generation" ... http://photos.prnewswire.com/prnh/20130307/600769 The convergence of ... giving hope for a better future to millions ... can measure glucose levels accurately and reliably have ...
(Date:12/13/2014)... SAN ANTONIO , Dec. 12, 2014 /PRNewswire/ ... presentation of data at the San Antonio Breast Cancer ... epoetin alfa plus best supportive care (BSC) versus BSC ... breast cancer receiving standard chemotherapy. This non-inferiority trial did ... out a 15 percent or greater increase in the ...
Breaking Biology Technology:Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12
... Pharmacyclics, Inc.,(Nasdaq: PCYC ) today announced that ... the company has regained compliance with Marketplace Rule,4450(a)(5) (the ... bid,price of the Company,s common stock. Nasdaq had previously ... stock had failed to maintain a,minimum bid price of ...
... 29 /Xinhua-PRNewswire-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" ... Republic of China ("PRC"),today reported solid financial results for ... Fourth Quarter Fiscal 2007 Highlights, -- ... the fourth quarter of 2006, ...
... Verizon Keynote at Leading Pharmaceutical Communication Event, Where Executives Gather to ... for Pharmaceutical, Biotech and Medical Technology ... ... pleased to announce the participation of two keynote speakers from the,U.S. Food ...
Cached Biology Technology:Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 2Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 3Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 4Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 5Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 6Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 7Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 8Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results 9FDA's Chief of Staff, Susan Winckler and Peter Thonis, Chief Communications 2FDA's Chief of Staff, Susan Winckler and Peter Thonis, Chief Communications 3
Proteinase K Buffer 3.9 ml...
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
Glutathione Agarose Beads 10 ml...
Anti-Ephrin B1 Host: rabbit polyclonal Species Reactivity: human Applications: WB Storage: 4C...
Biology Products: